SCHEMBL19205663

SCHEMBL19205663

CC(Nc1nccnc1-c1ccc(N)cc1)c1ccc(F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SOS1 Q07889 1/20 0.39
▸ TNF P01375 1/20 0.38
▸ PIK3CD O00329 7/20 0.38
▸ MAPK14 Q16539 2/20 0.38
▸ KIT P10721 1/20 0.37
▸ P2RX7 Q99572 2/20 0.37
▸ EGFR P00533 3/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ PIK3CG P48736 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NR1I2 O75469 1/20 0.35
▸ SCN1A P35498 1/20 0.35
▸ SCN1B Q07699 1/20 0.35
▸ SCN5A Q14524 1/20 0.35
▸ SCN8A Q9UQD0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19205662 1.00 SOS1 (0.39) SOS1TNFPIK3CDMAPK14KIT
SCHEMBL22270657 0.87 SOS1 (0.39) SOS1PIK3CDMAPK14P2RX7EGFR
SCHEMBL19205787 0.87 SOS1 (0.41) SOS1PIK3CDMAPK14KITEGFR
SCHEMBL19205789 0.87 SOS1 (0.41) SOS1PIK3CDMAPK14KITEGFR
SCHEMBL18485915 0.87 PIK3CD (0.36) TNFPIK3CDPIK3CGTP53
SCHEMBL19205792 0.85 PIK3CD (0.39) TNFPIK3CDPIK3CGSCN1ASCN5A
SCHEMBL18484164 0.85 PIK3CD (0.39) TNFPIK3CDPIK3CGSCN1ASCN5A
SCHEMBL19205805 0.84 TAAR1 (0.39) SOS1MAPK14P2RX7JAK2PIK3CG
SCHEMBL19205804 0.84 TAAR1 (0.39) SOS1MAPK14P2RX7JAK2PIK3CG
SCHEMBL18484178 0.77 TNF (0.41) TNFPIK3CDEGFRPIK3CGSCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108026050-B Novel compounds as ROR gamma modulators 格兰马克药品股份有限公司 2021-04-30 — — CN disclosed
US-10988467-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2021-04-27 — — US disclosed
EP-3686187-A1 PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2020-07-29 — — EP disclosed
EP-3331863-B1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2020-03-11 — — EP disclosed
US-20190256508-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2019-08-22 — — US disclosed
US-10344024-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2019-07-09 — — US disclosed
US-20180237428-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2018-08-23 — — US disclosed
US-9975887-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2018-05-22 — — US disclosed
US-20170233380-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10988467-B2 Compounds as ROR gamma modulators RORB, RORA, RORC SOS1 3287/4885TNF 386/4885PIK3CD 3634/4885
US-10344024-B2 Compounds as ROR gamma modulators RORB, RORA, RORC SOS1 3287/4885TNF 386/4885PIK3CD 3634/4885
US-20190256508-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS RORB, RORA, RORC SOS1 3603/4885TNF 437/4885PIK3CD 3730/4885
US-20180237428-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS RORB, RORA, RORC SOS1 2431/4885TNF 465/4885PIK3CD 4313/4885
US-20170233380-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS RORB, RORA, RORC SOS1 3603/4885TNF 437/4885PIK3CD 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback